For instance, among the small-molecule inhibitors, MCC950 can inhibit the NLRP3 inflammasome activation and subsequent release of pro-inflammatory cytokines, offering potential therapeutic benefits in diseases like gout, CAPS, and IBD [91,98,99]. This evidence concerns the gene NLRP3 and inflammatory bowel disease.